Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)

News provided by

Heptares Therapeutics

12 Sep, 2012, 17:38 GMT

WELWYN GARDEN CITY, England and BOSTON, September 12, 2012 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau, will represent the Company at the 5th CNS Partnering and Deal-making conference, which takes place  at the Hilton San Francisco Financial District, San Francisco, CA (13-14 September).

On 13 September, Mr Grau will be part of a panel discussion at 2:30pm (PST) entitled "Partnering in the AD, PD and other Cognitive Disorders. How Have Things Changed?"

On 14 September, Mr Grau will give a presentation in the Licensing and Partnering Strategies session at 10:15am (PST) entitled "Back to the Future in Neuroscience: A New Approach to Old (and Validated) Targets."

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases.  Our pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.

Heptares is pioneering the application of structure-based drug design to the GPCR superfamily of targets and is focused on creating molecules that modulate high-value, yet historically undruggable or challenging, GPCRs.  Our platform incorporates proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.

Using this approach, we have generated a broad pipeline of drug candidates for the treatment of serious disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, chronic insomnia, addiction disorders, and diabetes.  For more information about Heptares, please visit http://www.heptares.com.